May 23, 2022

Featuring perspectives from Dr Yelena Janjigian, including the following topics:

• Introduction (0:00)
• Management of HER2-Negative Gastroesophageal Cancers (2:10)
• Case: A man in his early 60s with HER2-negative metastatic squamous cell carcinoma of the esophagus; PD-L1 70% — Kapisthalam (KS) Kumar, MD (23:56)
• Case: A man in his late 50s with a history of GERD diagnosed with localized esophageal adenocarcinoma — Gurveen Kaur, MD (26:43)
• Case: A man in his early 50s with localized gastroesophageal-junction adenocarcinoma — G Richard Polkinghorn, MD (30:05)
• Case: A man in his early 80s with localized HER2-negative esophageal adenocarcinoma — Raymond Lobins, DO (33:24)
• Case: A man in his early 80s with HER2-negative metastatic gastric cancer; MSS, PD-L1 CPS 5 — Neil Morganstein, MD (35:44)
• Treatment for HER2-Positive Gastroesophageal Cancers (44:34)
• Case: A woman in her mid 60s with metastatic esophageal adenocarcinoma; PD-L1 CPS 5, HER2 amplification — Dr Kaur (49:58)
• Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (53:44)
• Journal Club with Dr Janjigian (57:37)

CME information and select publications